Braf-V600e immunohistochemical analyses in a series of 15, Caucasian patients affected by lentigo maligna.
作者信息
Dika Emi, Lambertini Martina, Fanti Pier Alessandro, Scarfì Federica, Corti Barbara, Altimari Annalisa, Ceccarelli Claudio, Pesci Silvia, Evangelista Valeria, Patrizi Annalisa
机构信息
Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy.
Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy.
出版信息
Acta Histochem. 2019 Apr;121(3):380-381. doi: 10.1016/j.acthis.2019.02.003. Epub 2019 Feb 20.
PMID:30797564
Abstract
摘要
相似文献
1
Braf-V600e immunohistochemical analyses in a series of 15, Caucasian patients affected by lentigo maligna.对15例患有恶性雀斑样痣的白种人患者进行Braf-V600e免疫组化分析。
Acta Histochem. 2019 Apr;121(3):380-381. doi: 10.1016/j.acthis.2019.02.003. Epub 2019 Feb 20.
2
The BRAF V600K mutation is more frequent than the BRAF V600E mutation in melanoma in situ of lentigo maligna type.在恶性雀斑样原位黑色素瘤中，BRAF V600K突变比BRAF V600E突变更常见。
J Invest Dermatol. 2014 Feb;134(2):548-550. doi: 10.1038/jid.2013.338. Epub 2013 Aug 9.
3
S100-negative junctional melanocytic proliferations.S100阴性的交界性黑素细胞增殖性病变
Am J Dermatopathol. 2011 May;33(3):327-9. doi: 10.1097/DAD.0b013e3181e031d1.
4
Expression of soluble adenylyl cyclase in lentigo maligna: use of immunohistochemistry with anti-soluble adenylyl cyclase antibody (R21) in diagnosis of lentigo maligna and assessment of margins.可溶性腺苷酸环化酶在恶性黑素瘤中的表达：使用抗可溶性腺苷酸环化酶抗体（R21）的免疫组织化学方法诊断恶性黑素瘤及评估边缘。
Arch Pathol Lab Med. 2012 Dec;136(12):1558-64. doi: 10.5858/arpa.2011-0617-OA.
5
Immunohistochemistry of pigmented actinic keratoses, actinic keratoses, melanomas in situ and solar lentigines with Melan-A.用Melan-A对色素性光化性角化病、光化性角化病、原位黑素瘤及日光性雀斑进行免疫组织化学检测。
J Cutan Pathol. 2008 Oct;35(10):931-4. doi: 10.1111/j.1600-0560.2007.00921.x. Epub 2008 May 20.
6
Acral lentiginous melanoma and mucosal melanoma expressed less programmed-death 1 ligand than cutaneous melanoma: a retrospective study of 73 Japanese melanoma patients.肢端雀斑样痣黑色素瘤和黏膜黑色素瘤程序性死亡配体1表达低于皮肤黑色素瘤：一项对73例日本黑色素瘤患者的回顾性研究
J Eur Acad Dermatol Venereol. 2019 Nov;33(11):e424-e426. doi: 10.1111/jdv.15742. Epub 2019 Jun 28.
7
KIT and BRAF mutational status in a patient with a synchronous lentigo maligna melanoma and a gastrointestinal stromal tumor.一名同时患有恶性雀斑样痣黑色素瘤和胃肠道间质瘤患者的KIT及BRAF突变状态
Am J Clin Dermatol. 2012 Feb 1;13(1):64-5. doi: 10.2165/11593910-000000000-00000.
8
Lentigo maligna and superficial spreading melanoma are different in their in situ phase: an immunohistochemical study.恶性雀斑和浅表扩散性黑色素瘤原位期的差异：一项免疫组织化学研究
Hum Pathol. 2002 Oct;33(10):1001-5. doi: 10.1053/hupa.2002.124014.
9
Lentigo maligna and lentigo maligna melanoma.恶性雀斑样痣和恶性雀斑样痣黑色素瘤。
J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):512. doi: 10.1016/s0190-9622(97)70166-x.
10
Differential expression of proliferation- and apoptosis-related markers in lentigo maligna and solar keratosis keratinocytes.恶性雀斑样痣和日光性角化病角质形成细胞中增殖和凋亡相关标志物的差异表达。
Am J Dermatopathol. 2003 Aug;25(4):300-7. doi: 10.1097/00000372-200308000-00004.
Zotero 插件